Registry Describing Clinical Information, Conventional, and Advanced Magnetic Resonance Imaging Information of Patients With Brain Glioma
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Adult Glioma
- Sponsor
- Asan Medical Center
- Enrollment
- 9000
- Locations
- 1
- Primary Endpoint
- Documentation of radiologic information of conventional MR imaging and advanced MR imaging
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
This registry aims to collect clinical and radiologic information including detailed clinical, conventional MR and advanced MR imaging data of patients with brain gliomas. Advanced MR imaging may include diffusion-weighted imaging, perfusion-weighted imaging (dynamic susceptibility contrast, arterial spin labeling, dynamic contrast enhancement), and chemical exchange saturation transfer (CEST) imaging. This registry will describe course of disease and long-term outcomes of brain gliomas.
Detailed Description
Though the cure for brain glioma- from low grade to glioblastoma- is yet to be found, seeking for curable treatment option is actively developing. Multimodal advanced MR imaging (contrast-enhanced T1 weighted imaging, diffusion-weighted imaging, chemical exchange saturation transfer imaging, and perfusion imaging) on 3 Tesla have shown potential in patients with glioma to monitor treatment response with quantitative assessment. To find suitable imaging biomarker for treatment response, assessing clinical and radiologic outcome for long-term is essential. The creation of a registry for brain glioma in long-term follow up provides an overview of the clinical, relevant treatment standards, advanced MR imaging information, and survival data of patients and thus create opportunities for imaging biomarker research.
Investigators
Ho Sung Kim
Associate Professor
Asan Medical Center
Eligibility Criteria
Inclusion Criteria
- •Patients must have radiologically and histologically confirmed diagnosis of Brain Glioma
- •Life expectancy of greater than 3 months
- •Must receive a first- or second-line therapy
- •Signed informed consent
Exclusion Criteria
- •No brain gliomas
- •Patients who have any type of bioimplant activated by mechanical, electronic, or magnetic means (e.g., cochlear implants, pacemakers, neurostimulators, biostimulates, electronic infusion pumps, etc), because such devices may be displaced or malfunction
- •Patients who are pregnant or breast feeding; urine pregnancy test will be performed on women of child bearing potential
Outcomes
Primary Outcomes
Documentation of radiologic information of conventional MR imaging and advanced MR imaging
Time Frame: 5 years per patient
Documentation of clinical information (demographics and Karnofsky performance score)
Time Frame: 5 years per patient
Documentation of treatment
Time Frame: 5 years per patient
Secondary Outcomes
- Progression Free Survival (PFS)(On-study date to lesser of date of progression or date of death from any cause (assessed at 6 months))
- One- year survival(One year)
- Identification of Imaging biomarkers of clinical significance (prognostic)(5 years)
- Overall Survival(5 years)